Diffuse Large B Cell Lymphoma (DLBCL) Clinical Trial
Official title:
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-naïve Patients With MCD Subtype DLBCL
The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT04824794 -
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04772989 -
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05169489 -
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
| Completed |
NCT01148446 -
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
|
Phase 3 | |
| Not yet recruiting |
NCT05934084 -
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
|
N/A | |
| Not yet recruiting |
NCT06050694 -
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
|
Phase 2 | |
| Active, not recruiting |
NCT04450069 -
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05366569 -
Bio-CAR-T BS Study
|
||
| Recruiting |
NCT05131022 -
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 |